Issue Date: October 28, 2013
Novartis Invests In Start-up Sideris
Novartis has signed a pact giving it the exclusive right to acquire Sideris Pharmaceuticals, a University of Florida spin-off, for up to $300 million. The deal is a companion to a $32 million fund-raising round for the biotech firm that was led by the venture capital company MPM Capital. Based in Boston and Gainesville, Fla., Sideris has developed SP-420, a small molecule that selectively binds iron and removes it from the body. It is intended to treat iron overload caused by multiple transfusions.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society